GE's AngioViz Approved by FDA
New product uses parametric imaging to give more infomation than DSA alone
GE Healthcare has recieved FDA clearance of AngioViz, an application that gives doctors a new visualization of vascular flow on a single image, helpful during complex interventional radiology procedures.
AngioViz provides a new visualization of the vascular flow seen in Digital Subtraction Angiography (DSA) imaging utilizing a technique called parametric imaging. AngioViz looks at each pixel in the image series and determines two things-the peak value of opacification caused by the contrast, and the time it takes for that pixel to reach peak opacification. These two parameters can be displayed as separate images or combined into a single color-coded image that represents parameters of vascular flow. This enables doctors to perceive parameters of flow quickly to support decision-making. In addition, AngioViz allows easy comparison of parametric images from different DSA acquisitions, such as pre- and post-treatment images. This can help physicians understand the impact on flow dynamics of various interventional treatments.
AngioViz bold flow visualization has the potential to be applied to a variety of clinical situations
· Help see where a blocked artery diminishes blood flow in the brain or other tissue
· Identify the timing and amount of blood flow in abnormal vessel anatomy
· Observe flow in abnormal tissue before and after treatment to support interventional oncology treatment
· Visualize peripheral artery blood flow before and after balloon angioplasty and stenting
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
